Conclusion Our preliminary study demonstrated that salidroside can provide a protective effect against epirubicin-induced GDC 0449 early left ventricular regional systolic dysfunction in patients with breast cancer, and the protective effects IWP-2 provided by salidroside may be explained by its reduction of oxidative stress. Acknowledgments Hua Zhang and Wei-sheng Shen contributed equally to this study. This project was supported by WuXi Health (grant no. ZXM0806). None of the authors have any conflicts of interest that are directly relevant
to the content of this article. References 1. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185–229.PubMedCrossRef 2. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 2006; 33: S2–7.PubMedCrossRef 3. Zhou X, Wu Y, Wang X, et al. Salidroside production by hairy roots of Rhodiola sachalinens is obtained after transformation with Agrobacterium rhizogenes. Biol Pharm Bull 2007; 30: 439–42.PubMedCrossRef 4. Wu T, Zhou H, Jin Z, et al. Cardioprotection of salidroside from ischemia/reperfusion injury by increasing N-acetylglucosamine linkage
to cellular proteins. Eur J Pharmacol 2009; www.selleckchem.com/products/Fedratinib-SAR302503-TG101348.html 613: 93–9.PubMedCrossRef 5. Mercuro G, Cadeddu C, Piras A, et al. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 2007; 12: 1124–33.PubMedCrossRef 6. Mantovani G, Maccio A, Madeddu C, et al. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer 2002; 98: 84–91.PubMedCrossRef 7. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13: 699–709.PubMedCrossRef 8. Mantovani Astemizole G, Madeddu C, Cadeddu C, et al. Persistence, up to
18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 2008; 13: 1296–305.PubMedCrossRef 9. Jassal DS, Han SY, Hans C, et al. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy. J Am Soc Echocardiogr 2009; 22: 418–24.PubMedCrossRef 10. Ferreira AL, Matsubara LS, Matsubara BB. Anthracycline-induced cardiotoxicity. Cardiovasc Hematol Agents Med Chem 2008; 6: 278–81.PubMedCrossRef 11. Zweier JL, Talukder MAH. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res 2006; 70: 181–90.PubMedCrossRef 12. Becker LB.